Using ultrasound to deliver cancer drugs directly to liver tumors
Drug-Loaded Nanobubbles for Ultrasound Enhanced Delivery to Colon Cancer Liver Metastasis
This study is testing a new way to deliver chemotherapy directly to liver tumors in patients with advanced colorectal cancer using tiny bubbles that can be activated by sound waves, which could help make the treatment more effective and reduce side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-10696225 on NIH RePORTER |
What this research studies
This research focuses on developing drug-loaded nanobubbles that can be activated by ultrasound to enhance the delivery of chemotherapy directly to liver metastases from colorectal cancer. By utilizing ultrasound technology, the researchers aim to improve drug concentration at the tumor site while minimizing systemic toxicity. The approach involves injecting these nanobubbles into the bloodstream, where they can be targeted and activated in real-time, potentially leading to more effective treatment outcomes for patients with advanced cancer. The study aims to address the limitations of current chemotherapy methods, which often result in low drug uptake and significant side effects.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with colorectal cancer who have developed liver metastases and are seeking more effective treatment options.
Not a fit: Patients with early-stage colorectal cancer or those without liver metastases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve treatment efficacy for patients with liver metastases from colorectal cancer, potentially extending survival and enhancing quality of life.
How similar studies have performed: Other research has shown promise in using ultrasound for targeted drug delivery, indicating that this approach could be a viable and innovative treatment strategy.
Where this research is happening
Cleveland, United States
- Case Western Reserve University — Cleveland, United States (Active)
Researchers
- Principal investigator: Exner, Agata a — Case Western Reserve University
- Study coordinator: Exner, Agata a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.